Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Terminated 5Recruiting 5Withdrawn 2Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Osteosarcoma 1Neoplasms 1Meningeal Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × aldesleukin × Clear all
NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡